Latest news with #NadineHachach-Haram
Business Wire
16-07-2025
- Business
- Business Wire
Proximie and HistoSonics Sign U.S. Partnership to Revolutionize Treatment of Liver Tumors
BOSTON--(BUSINESS WIRE)--Proximie (the 'Company'), the leading global health technology platform digitizing operating rooms, announces a partnership with HistoSonics, the manufacturer of the Edison ® Histotripsy System 1 and novel histotripsy therapy platforms used for non-invasive treatment of liver tumors. Dividends for surgeons and clinical teams are multiple: increased productivity; access to operational best practices; medical innovation, and improved patient outcomes. The U.S.-focused partnership demonstrates the value Proximie's cloud-based operating system designed for intelligent ORs offers to medical device companies, as the Company enhances the adoption and user experience of HistoSonics' Edison System. Proximie's OR intelligence platform offers a tailored digital ecosystem which drives healthcare innovation. The platform facilitates real-time connectivity; unified data – including data capture, structure, and control capabilities; AI-enabled insight; and a context-rich video library. Within the partnership, Proximie and HistoSonics integrate the Proximie platform and the Edison System to hospitals and ambulatory surgery centers across the U.S., providing significant value for healthcare system operators, physicians, and patients. Specifically, Proximie's real-time connectivity capabilities enable HistoSonics' medical directors and physician faculty to share live expertise to surgeons using the Edison System; treating patients' liver tumors more effectively via focused ultrasound sonic beam therapy; while adding new levels of rapidity to HistoSonic's diagnostics and operations. The dividends for surgeons and clinical teams are multiple: increased productivity; access to operational best practices; medical innovation, and improved patient outcomes. Initial go-live regions for the partnership include Chicago, Colorado, Florida, Louisiana, Seattle, and Southern California. Almost 300,000 patients in the U.S. alone are diagnosed with tumors in the liver, most of which originate from organs outside the liver like the colon, rectum, and pancreas, and travel to the liver. While these metastatic tumors appear in advanced stages, even primary tumors of the liver (Hepatocellular carcinoma) have a dismal 5 year survival rate of less than 18%. With the substantial unmet clinical need from so many tumors in the liver the potential for real-time histotripsy procedural support via Proximie could prove to dramatically impact patient outcomes. Dr. Nadine Hachach-Haram, Founder and CEO of Proximie, commented: 'We are thrilled to announce our partnership with HistoSonics, driving the rollout of the cutting-edge Histotripsy System while making a tangible impact on outcomes for those suffering from liver tumors. The partnership is testament to the benefits of intelligent digital connectivity within the OR; enabled by the Proximie platform; providing value to stakeholders across the healthcare ecosystem.' Mike Blue, President & CEO of HistoSonics, said: 'Our partnership with Proximie represents our commitment to partner with world leaders in their respective domains, providing our customers with the best technology solutions possible. Proximie's ability to provide real-time virtual presence in histotripsy procedures provides opportunities for our medical team to share expertise with physicians across the world and support our customers in unprecedented ways.' The Company's partnership with HistoSonics has already yielded dividends for surgeons and patients. Notably, Dr. Kevin Burns of Providence Mission Hospital has frequently utilized the Proximie platform and the Edison Histotripsy System together, benefiting patients and enabling knowledge-sharing opportunities. Dr. Kevin Burns, Chief of Interventional Radiology at Providence Mission Hospital, said: "HistoSonics' Edison Histotripsy System has drastically improved outcomes for our patients suffering with liver tumors. The system's ability to destroy tumors via non-thermal, non-invasive, personalized therapy significantly reduces recovery times - getting patients out of hospital and back on their feet more quickly, while improving our productivity and operational efficiency. Additionally, the opportunity for clinicians to share live guidance when using the Histotripsy system, via the Proximie platform, is invaluable - ensuring physicians can be confident when performing novel histotripsy therapy for the first time; guaranteeing access to cutting-edge techniques for more patients." The announcement follows recent partnerships between Proximie and numerous global MedTech players. Notably, the Company recently announced a global partnership with Olympus Corporation – the medical technology company and market leader in innovative surgical tools and endoscopy systems; and a partnership with Distalmotion – the surgical robotics pioneer and developer of the Dexter surgical robot. To date, Proximie is deployed across five continents and is working with hundreds of healthcare systems and major medical device developers – creating a truly global impact by improving access to high-quality surgical care in both developed and developing economies. Notes to Editors About Proximie Proximie is a global health technology platform focused on digitizing operating and diagnostic rooms. Proximie's mission is to make surgery more accessible, efficient, and effective for everyone, via cutting-edge, cloud-based technology. Proximie's OR intelligence platform offers a tailored digital ecosystem which drives healthcare innovation. The platform facilitates real-time connectivity, unified data – including data capture, structure, and control capabilities, – AI-enabled insight, and a context-rich video library This provides benefits for the entire healthcare ecosystem via improved productivity, optimized workflows, accelerated training, and enhanced medical technology innovation; benefiting patient outcomes. By opening-up surgery beyond traditional operating room boundaries, Proximie is facilitating a rich, insightful data set which naturally feeds best practices into the entire healthcare ecosystem. Founded by Dr. Nadine Hachach-Haram, Proximie has now been deployed in over 800 hospitals across 50 countries in five continents. Proximie has contracts with over 40 major medical device companies – with access to 90% of operating rooms and diagnostic suites in the U.K., U.S., and EU – and been published in over 20 medical journals. Proximie is the lead author of a report on ' Patient safety in surgery – the urgent need for reform ', highlighting the challenges affecting patient safety in surgery in the NHS as well as potential solutions to improve patient safety. For more information, please visit or follow @Proximie on X and LinkedIn. About HistoSonics HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota. The Edison ® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any specific disease or condition. Use of the Edison System in kidney applications is limited by federal law to investigational use. The #HOPE4KIDNEY Trial is designed to support a future expansion of the indication to include the destruction of kidney tissue/tumors. 1 HistoSonics' Edison ® Histotripsy System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control. The novel mechanism of action of this proprietary technology may provide significant patient advantages, including the ability of the treatment site to recover and resorb quickly. HistoSonics' platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today.
Business Wire
15-07-2025
- Business
- Business Wire
Global Healthtech Proximie Partners With U.S. MedTech Pioneer Imperative Care – Driving Development of Robotic Stroke Treatment System
LONDON--(BUSINESS WIRE)-- Proximie (the 'Company'), the leading global health technology platform digitising operating rooms ('OR'), announces a partnership with U.S.-based medical technology company, Imperative Care – with the aim of driving the development of a robotic surgical system to treat ischemic stroke. Imperative Care researches, develops and manufactures connected innovations to elevate care for people affected by devastating vascular diseases such as strokes and pulmonary embolisms; addressing specific gaps in treatment and care to transform the entire patient journey. The partnership supports physicians in the use of Imperative Care's Telos robotic-assisted technology platform. The platform, currently in development, is designed to enable physicians to perform aspiration thrombectomy procedures, both on-site and remotely (via telesurgery), to treat stroke patients. Patients will benefit from improved access to cutting-edge treatments regardless of their location – saving lives across both developed and developing economies. A key part of the Telos platform's functionality is the integration of Proximie's Software Development Kit ('SDK') at a system level; allowing audio, video, and telemetry data to be shared with the physicians performing the procedure, through a customised, Telos-specific, tenant of the Proximie platform. Proximie's SDK helps medical device developers improve patient outcomes, and surgical productivity, by enhancing the innovation and development of medical technology systems used across the OR. Specifically, the SDK allows developers to obtain data on how devices perform in real-world surgeries – contributing to development of new technologies and robotic surgical systems, supercharging MedTech performance. With over 12 million strokes occurring globally each year; resulting in an economic cost of over US$890 billion 1; the collaboration between Proximie and Imperative Care is an important step toward reducing the human and economic cost of strokes through improved treatment. Dr. Nadine Hachach-Haram, Founder and CEO of Proximie, said: "Proximie shares Imperative Care's commitment to making stroke thrombectomy available to more patients, bringing treatment to those who might not otherwise have timely access to this hugely impactful therapy – both on-site and remotely via telesurgery. 'The integration of Proximie's SDK within the Telos robotic-assisted platform clearly demonstrates the value Proximie is providing to medical robotics developers and surgeons. We look forward to working with Imperative Care as it continues to develop this novel technology.' Richard Leparmentier, Chief Technology Officer of Imperative Care, commented: 'Our Telos robotics platform is fundamental to the way we think at Imperative Care about the future of stroke and vascular care, and we are pleased to be working with Proximie toward the goal of making this visionary technology available to patients.' Fred Khosravi, Chairman and CEO of Imperative Care, added: 'Aspiration thrombectomy is one of the most powerful treatments in all of medicine, and yet in the United States today, approximately 80% of all ischemic stroke patients who are candidates for this treatment are not receiving this vital care 2 – and in other parts of the world, the treatment gap is much higher. At Imperative Care, we believe that one of the most effective means of addressing this shortcoming of care is to utilize robotics and automation to dramatically expand the reach of thrombectomy and make timely, effective treatment available to the entire population.' In addition to integrating the SDK in partners' medical devices, Proximie also uses the SDK in the Company's plug-and-play hardware products; including the PxKit; emphasising the developmental benefits made possible by the SDK. The announcement follows recent partnerships between Proximie and numerous global MedTech players. Notably, the Company recently announced a global partnership with Olympus Corporation - the medical technology company and market leader in innovative surgical tools and endoscopy systems; and a partnership with Distalmotion – the surgical robotics pioneer and developer of the Dexter surgical robot. To date, Proximie is deployed across five continents and is working with hundreds of healthcare systems and major medical device developers – creating a truly global impact by improving access to high-quality surgical care in both developed and developing economies. Notes to Editors About Proximie Proximie is a global health technology platform focused on digitizing operating and diagnostic rooms. Proximie's mission is to make surgery more accessible, efficient, and effective for everyone, via cutting-edge, cloud-based technology. Proximie's OR intelligence platform offers a tailored digital ecosystem which drives healthcare innovation. The platforms facilitates real-time connectivity, unified data including data capture, structure, and control capabilities, – AI enabled insight, and a context-rich video library. This provides benefits for the entire healthcare ecosystem via improved productivity, optimized workflows, accelerated training, and enhanced medical technology innovation; benefitting patient outcomes. By opening-up surgery beyond traditional operating room boundaries, Proximie is facilitating a rich, insightful data set which naturally feeds best practices into the entire healthcare ecosystem. Founded by Dr. Nadine Hachach-Haram, Proximie has now been deployed in over 800 hospitals across 50 countries in five continents. Proximie has contracts with over 40 major medical device companies – with access to 90% of operating rooms and diagnostic suites in the U.K., U.S., and EU – and been published in over 20 medical journals. Proximie is the author of a report on ' A cut above: optimizing efficiency in operating rooms', highlighting strategies to maximize OR utilization and deliver more operations for patients without compromising quality of care. For more information, please visit or follow @Proximie on X and LinkedIn. About Imperative Care, Inc. Imperative Care is a commercial-stage medical technology company researching, developing and manufacturing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. The robotic system described herein is not approved or available for sale.
Business Wire
11-06-2025
- Health
- Business Wire
Guy's and St Thomas' Collaborates With Leading AI Companies to Transform Healthcare Delivery
LONDON--(BUSINESS WIRE)--Guy's and St Thomas' NHS Foundation Trust has announced the launch of the Proactive & Accessible Transformation of Healthcare (PATH) initiative in collaboration with General Catalyst, NVIDIA, Hippocratic AI, and Sword Health. PATH brings together leading technology companies to explore comprehensive solutions to deliver the NHS's vision of the 'three shifts' - from hospital to community, analogue to digital, and treatment to prevention. Through harnessing frontier machine learning and agentic AI technologies, PATH aims to transform NHS care delivery - enabling a more proactive, coordinated, and efficient health system, and laying the foundation for a scalable, national model of population health. Professor Ian Abbs, CEO of Guy's and St Thomas', said: 'Our Strategy to 2030 set out a bold ambition to deliver better, faster, fairer healthcare for all. PATH seeks to bring that ambition to life - combining cutting-edge technology and clinical care to build a more proactive NHS.' Dr. Nadine Hachach-Haram, Clinical Lead for Innovation at Guy's and St Thomas', said: 'This is a first for the NHS - rethinking pathways end-to-end with AI at the centre, from referral to recovery. We're aiming not just to treat more patients, but to treat them better." Tackling the Elective Care Crisis with Proven AI Solutions PATH will first target one of the Trust's most urgent challenges: the elective care waiting list. At Guy's and St Thomas' alone, over 53,000 patients are waiting for a first appointment, and 25,000 are awaiting surgery. PATH will explore end-to-end solutions that go further than just managing waiting lists - it aims to transform the patient journey entirely. Through integrating AI-powered patient support, remote monitoring, and virtual care technologies, PATH will enable Guy's and St Thomas' clinicians to prioritise cases based on clinical need, help patients become active participants in their care, and ensure resources are allocated efficiently across the system. The result should be a more responsive healthcare model that provides timely access while maintaining quality and the human aspects of care delivery. PATH combines: Guy's and St Thomas' Centre of Innovation, Transformation, and Improvement (CITI), with its mission to support the Trust to deliver better, faster, fairer healthcare. Hippocratic AI's Safety-focused Generative AI Healthcare Agents, powered by its clinically proven and patented Polaris safety constellation architecture, conduct non-diagnostic patient-facing outreach. To date, more than 2.49 million patient calls have been made with a high average patient satisfaction rating of 8.95/10. Sword Health's AI Care platform has already treated over 500,000 patients globally across physical pain, pelvic health, and other clinical areas, delivering 6.5 million AI sessions to date and saving nearly $1 billion in unnecessary healthcare costs. NVIDIA Inception for startups, including technical tools and training for AI developers, preferred pricing on NVIDIA hardware and software, and opportunities to connect with NVIDIA's network of venture capital firms. General Catalyst's health system expertise to identify transformative technology providers and align incentives through shared-savings models that drive measurable impact. Munjal Shah, Founder and CEO of Hippocratic AI, said: "Our safety-focused generative AI healthcare agents open the door to the age of healthcare abundance in the UK. More personalized care will help patients feel more supported and heard, expanding access to care and improving outcomes." Virgílio Bento, Founder & CEO of Sword Health, said: "At Sword Health, we've delivered AI Care to more than half a million patients to date, leading to higher access and quality, reducing waste, and materially improving clinical outcomes. Our ambition is to turn waiting lists into recovery journeys." Howard Wright, VP of startup ecosystem, NVIDIA, said: 'AI is driving a new era in healthcare that is smart, fast, and even more patient-centric. This collaboration helps build upon the transformative impact that innovative startups can have when advanced AI is harnessed to serve public health." A Scalable Model for the Future NHS PATH could be a blueprint for a new operating model for the NHS. NHS care teams, augmented with intelligent systems, will be able to better manage chronic conditions, coordinate care, and deliver patient support. Patient care will shift from reactive to proactive, and access to care will be improved. Technology can extend the reach of NHS teams and enable a workforce model designed for quality, sustainability, speed, and scale. , Managing Director at General Catalyst, said: "The goal of PATH is to enable the NHS to work better for everyone, starting with Guy's and St Thomas'. By deploying applied AI to increase access, improve care, optimise resources, and empower staff, we believe we can build an NHS fit for the future."
